CDEK
← All drugs Report issue

89zr-trastuzumab

mAbexperimentalImaging agent

Clinical trial activity

8 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2011 (NCT01420146)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No
Imaging
89-Zirconium

Oral

No

Parenteral

No

Topical

No

Also known as

  • 89zr-dfo-trastuzumab
  • (89)zr-trastuzumab
  • 89zr-trastuzumab
  • 89zr-trastuzumab
  • zirconium-89-trastuzumab
  • zr89-trastuzumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04757090Phase 2Dec 31, 2021Molecular Templates, Washington University in St. Louis
NCT03321045Early Phase 1 (Phase 1)Nov 21, 2017University of Alabama, Birmingham
NCT02286843N/ANov 1, 2014Cornell University, Department of Defense, Genentech
NCT02065609Early Phase 1 (Phase 1)Feb 1, 2014National Cancer Institute (NCI), Washington University in St. Louis
NCT02023996N/ADec 1, 2013Cornell University, Department of Defense
NCT01832051Phase 2Mar 1, 2013University of Groningen
NCT01565200Phase 2May 1, 2012Free University of Brussels, Roche
NCT01420146Phase 1Aug 1, 2011Free University of Brussels
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cornell UniversityAcademic/Hospital2212013
Department of DefenseGovernment2012013
Free University of BrusselsAcademic/Hospital2222011
Washington University in St. LouisAcademic/Hospital2222014
GenentechFor profit1012014
Molecular TemplatesFor profit1012021
National Cancer Institute (NCI)Government1012014
RocheFor profit1012012
University of Alabama, BirminghamAcademic/Hospital1112017
University of GroningenAcademic/Hospital1112013
10 organizations
Page 1 / 1